Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer

Дата публикации: 30-07-2026 00:00:00

This randomized clinical trial evaluates the combination of anti−programmed death-1 cemiplimab and anti−lymphocyte activation gene 3 added to neoadjuvant therapy in ERBB2-negative early-stage high-risk breast cancer.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
2	Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer	0	7.64	01-10-2024
3	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
4	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
5	Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer	0	12.99	13-08-2026
6	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
7	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023
8	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
9	Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer	0	13.41	03-08-2026
10	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.85. Источник: archderm.jamanetwork.com.